XML 44 R33.htm IDEA: XBRL DOCUMENT v3.24.3
Stockholders' Equity (Tables)
9 Months Ended
Sep. 30, 2024
Stockholders' Equity Note [Abstract]  
Schedule of Stock Option Activity
The following table summarizes stock option activity during the nine months ended September 30, 2024:
SharesWeighted-
Average 
Exercise
Price
Weighted-
Average
Remaining
Contractual
Term
Aggregate
Intrinsic Value
(in thousands)(in years)(in thousands)
Outstanding at December 31, 2023
2,710 8.145.1$26,383 
Granted— — 
Exercised(125) 2.48
Cancelled/forfeited(33)11.92 
Outstanding at September 30, 2024
2,552  8.38 4.2$5,466 
Vested and exercisable at September 30, 2024
2,100  6.63 3.2$5,466 
Schedule of RSU, PSU, MPSUs Activity
The following table summarizes RSU activity during the nine months ended September 30, 2024:
Number of SharesWeighted-Average 
Grant Date Fair Value Per Share
(in thousands)
Unvested RSUs as of December 31, 2023
11,244 $17.46 
Granted9,813 11.83 
Vested(6,180)16.95 
Cancelled/forfeited(1,116)17.51 
Unvested RSUs as of September 30, 2024
13,761 $13.73 
Number of SharesWeighted-Average Grant Date Fair Value Per Share
(in thousands)
Nonvested PSUs as of December 31, 2023
732 $16.49 
Granted909 12.60 
Vested(239)16.41 
Cancelled/forfeited(271)16.43 
Nonvested PSUs as of September 30, 2024
1,131 $13.40 
Number of SharesWeighted-Average Grant Date Fair Value Per Share
(in thousands)
Nonvested MPSUs as of December 31, 2023
1,471 $6.46 
Granted— — 
Vested— — 
Cancelled/forfeited(158)6.56 
Nonvested MPSUs as of September 30, 2024
1,313 $6.45 
Schedule of Stock-Based Compensation Expense
The following table summarizes the components of total stock-based compensation expense included in the accompanying condensed consolidated statements of operations:
Three months ended September 30,Nine months ended September 30,
2024202320242023
(in thousands)
Cost of revenue$1,911 $2,860 $6,734 $8,378 
Research and development7,378 12,122 25,684 35,808 
Sales and marketing7,113 9,061 22,014 25,643 
General and administrative8,614 11,670 28,553 31,027 
Total stock-based compensation expense$25,016 $35,713 $82,985 $100,856